Navigation Links
Denis Connaghan Joins Clinverse, Inc. as Chief Executive Officer
Date:8/21/2013

Raleigh, NC (PRWEB) August 21, 2013

Clinverse, Inc., a global technology and eclinical commerce network for clinical trials, announced today the addition of Denis Connaghan as Chief Executive Officer. Denis brings more than 25 years of substantial commercialization experience across industry sectors including technology, healthcare, insurance, life sciences and IT.

Prior to joining Clinverse, Denis served as a management consultant and in interim executive roles at GMA Healthcare, Infina Connect and several other life science IT and services companies. Additionally, he served as the CEO of etrials Worldwide, an eclinical solutions provider to pharmaceutical companies, prior to its acquisition by Merge Healthcare.

“I’m thrilled to join such a fast-paced, growing company,” expressed Connaghan. “Clinverse’s FLS platform is an industry-first and continues to outpace the industry in terms of innovation. We are well positioned to build on this solid technology foundation, and I look forward to working with the Clinverse team to capitalize on my global and industry expertise to drive additional opportunities in the clinical trial services market.”

With the announcement of Denis as CEO, Tim Immel, founder and former CEO of Clinverse, will take on the role of Chief Product Officer. In his new position, Tim will dedicate 100 percent of his commitment and direct attention to pursuing product excellence and ensuring the company maintains and grows its undisputed lead in the area of financial lifecycle systems for the clinical trials industry.

“Of all the many responsibilities I have had at Clinverse, none has been more important to the business or more gratifying to me personally than to design and build the exceptional products and services that we offer, products that fill an important yet unmet need in the marketplace,” said
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Michael Cusumano, MITs Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
2. Robert Farrell Joins Bionovos Board of Directors
3. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
4. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
5. First Choice Rehabilitation Specialists Joins Select Medical
6. Excel Life Sciences Joins DATATRAKs Connect Partner Program
7. Marina Biotech, Inc. Joins OTCQX
8. Richard H. Scheuermann, Ph.D. Joins J. Craig Venter Institute as Director of Informatics
9. Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
10. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
11. Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 2011 Jennerex, Inc., a private clinical-stage biotherapeutics ... first-in-class targeted oncolytic virus products for cancer, together ... enrollment has been initiated and the first patient ... trial called TRAVERSE.  The trial is evaluating the ...
... BRISBANE, Calif., Nov. 3, 2011 InterMune, Inc. (NASDAQ: ... for the third quarter and nine months ended September ... clinical development activities, including the launch of Esbriet® (pirfenidone) ... Executive Officer and President of InterMune said, "The third ...
... 3, 2011 Reportlinker.com announces that a new ... Global Biochip Markets: Microarrays ... INTRODUCTION  ... BCC,s goal for this study was to determine ...
Cached Biology Technology:Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 2Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 3Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 4Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 5Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 6InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 2InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 3InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 4InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 5InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 6InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 7InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 8Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Global Biochip Markets: Microarrays and Lab-on-a-Chip 5
(Date:4/17/2014)... NY, April 17, 2014The development of stem cell therapies ... ability to characterize stem cell populations based on cell ... discovered a new marker that is highly expressed in ... cord blood, which they describe in an article in ... Mary Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
(Date:4/17/2014)... anthrax detection cartridge developed at Sandia National Laboratories and ... easier, faster and cheaper. , Bacillus anthracis ... in soils all over the world and can cause ... animals. The bacteria can survive in harsh conditions for ... may occur through skin contact, inhalation of spores or ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... BIRMINGHAM, Ala. The U.S. Department of Energy (DOE) ... of Alabama at Birmingham (UAB) School of Engineering on ... the capture and permanent safe storage, or sequestration, of ... Southern Company, the parent company of Alabama Power. ...
... is publishing a special issue "Beyond the Origin: Charles ... of Species which was published 150 years ago in November ... Dr. Ulrich Kutschera, professor of plant physiology and evolutionary biology ... this special issue are available free of charge until 30 ...
... brilliance of butterfly wings has inspired a 3.2m, three-year ... fields of security, energy and the environment. The University ... signed a collaborative contract to develop new technologies based ... next three years a team of physicists from the ...
Cached Biology News:UAB, partners seek safe carbon dioxide storage for 'greener' power generation 2UAB, partners seek safe carbon dioxide storage for 'greener' power generation 3£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2
a1-Antitrypsin (human, alpha-1 AT)...
... vesicles are used to study co-translational ... Processing events such as signal peptide ... glycosylation can be examined by the ... vitro in the presence of these ...
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... New Concept in Microarrays: Biomedical Photometrics Inc. ... GmbH (Jena, Germany) have collaborated to develop ... ArrayTube System. The DNAscope AT is ... new DNAscope AT automatically reads up to ...
Biology Products: